Skip to content

Study · Observational study · n = 43,352 · 2025

10 results

Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.

Tabatabai L, Cosman F, Curtis JR, DeSapri KT, LaBaume CT, Reginster JY, Rizzoli R, Cortet B, Wang Y, Chiodo J 3rd, Mitlak BH

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists16 Nov 2024Cited by 14 (Europe PMC)

PMID39551187 (opens in a new tab)DOI10.1016/j.eprac.2024.10.017 (opens in a new tab)PepBankPUB-39551187
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

BackgroundAbaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture. In the Abaloparatide Comparator Trial In Vertebral Endpoints study, bone mineral density improvements were significantly greater with abaloparatide compared to teriparatide at the total hip and femoral neck. We conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.MethodsThis retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide. The index date was the date of the initial prescription dispensed. Times to first hip fracture, nonvertebral fracture, and serious cardiovascular event were compared between logistic regression-based propensity score-matched cohorts and in predefined subgroups by age, prior antiresorptive use, and prior fracture using Cox proportional hazards models.ResultsPatients (21 676 per cohort) were well matched on 73 baseline parameters. Forty-five percent of patients in the abaloparatide arm and 47% in the teriparatide arm were exposed to treatment for longer than 12 months. Over 18 months (+ 30 days follow-up), 245 (1.1%) and 296 (1.4%) women in the abaloparatide and teriparatide cohorts, respectively, had a hip fracture (HR [95% CI] 0.83 [0.70, 0.98]; P = .027); 947 (4.4%) and 1078 (5.0%) had a nonvertebral fracture (0.88 [0.80, 0.96]; P = .003). There were no significant treatment-subgroup interactions (P ≥ .2). Cardiovascular events were similar between groups.ConclusionsThere were significantly lower rates of hip and nonvertebral fractures with abaloparatide compared to teriparatide, which were consistent across subgroups. No differences in cardiovascular safety were noted between cohorts.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In matched women aged 50 years or older, abaloparatide was linked to lower hip fracture risk than teriparatide over 18 months.

    In plain wordsAbaloparatide was linked to fewer hip fractures than teriparatide in matched women.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseHip fracture incidence
    Study

    n = 43,352

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Measurements

    Hip fracture events
    245 women
    abaloparatide cohort
    Hip fracture incidence
    1.1%
    abaloparatide cohort
    Hip fracture events
    296 women
    teriparatide cohort
    Hip fracture incidence
    1.4%
    teriparatide cohort
    Hazard ratio
    0.83 ratio
    abaloparatide versus teriparatide
    Hazard ratio 95% CI
    0.7 to 0.98 ratio
    abaloparatide versus teriparatide

    Source sentences

    Summary
    Over 18 months (+ 30 days follow-up), 245 (1.1%) and 296 (1.4%) women in the abaloparatide and teriparatide cohorts, respectively, had a hip fracture (HR [95% CI] 0.83 [0.70, 0.98]; P = .027)
    2 context sentences
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  2. 02HumanObservational studyEfficacy outcome

    In matched women aged 50 years or older, teriparatide was linked to higher hip fracture risk than abaloparatide over 18 months.

    In plain wordsTeriparatide was linked to more hip fractures than abaloparatide in matched women.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseHip fracture incidence
    Study

    n = 43,352

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Measurements

    Hip fracture events
    245 women
    abaloparatide cohort
    Hip fracture incidence
    1.1%
    abaloparatide cohort
    Hip fracture events
    296 women
    teriparatide cohort
    Hip fracture incidence
    1.4%
    teriparatide cohort
    Hazard ratio
    0.83 ratio
    abaloparatide versus teriparatide
    Hazard ratio 95% CI
    0.7 to 0.98 ratio
    abaloparatide versus teriparatide

    Source sentences

    Summary
    Over 18 months (+ 30 days follow-up), 245 (1.1%) and 296 (1.4%) women in the abaloparatide and teriparatide cohorts, respectively, had a hip fracture (HR [95% CI] 0.83 [0.70, 0.98]; P = .027)
    2 context sentences
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  3. 03HumanObservational studyEfficacy outcome

    In matched women aged 50 years or older, abaloparatide was linked to lower nonvertebral fracture risk than teriparatide over 18 months.

    In plain wordsAbaloparatide was linked to fewer fractures outside the spine than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseNonvertebral fracture incidence
    Study

    n = 43,352

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Measurements

    Nonvertebral fracture events
    947 women
    abaloparatide cohort
    Nonvertebral fracture incidence
    4.4%
    abaloparatide cohort
    Nonvertebral fracture events
    1078 women
    teriparatide cohort
    Nonvertebral fracture incidence
    5%
    teriparatide cohort
    Hazard ratio
    0.88 ratio
    abaloparatide versus teriparatide
    Hazard ratio 95% CI
    0.8 to 0.96 ratio
    abaloparatide versus teriparatide

    Source sentences

    Summary
    947 (4.4%) and 1078 (5.0%) had a nonvertebral fracture (0.88 [0.80, 0.96]; P = .003).
    3 context sentences
    Summary · context
    We conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  4. 04HumanObservational studyEfficacy outcome

    In matched women aged 50 years or older, teriparatide was linked to higher nonvertebral fracture risk than abaloparatide over 18 months.

    In plain wordsTeriparatide was linked to more fractures outside the spine than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseNonvertebral fracture incidence
    Study

    n = 43,352

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Measurements

    Nonvertebral fracture events
    947 women
    abaloparatide cohort
    Nonvertebral fracture incidence
    4.4%
    abaloparatide cohort
    Nonvertebral fracture events
    1078 women
    teriparatide cohort
    Nonvertebral fracture incidence
    5%
    teriparatide cohort
    Hazard ratio
    0.88 ratio
    abaloparatide versus teriparatide
    Hazard ratio 95% CI
    0.8 to 0.96 ratio
    abaloparatide versus teriparatide

    Source sentences

    Summary
    947 (4.4%) and 1078 (5.0%) had a nonvertebral fracture (0.88 [0.80, 0.96]; P = .003).
    3 context sentences
    Summary · context
    We conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  5. 05HumanObservational studyEfficacy outcome

    In matched women, the abaloparatide versus teriparatide comparison showed no significant treatment-subgroup interactions.

    In plain wordsThe abaloparatide versus teriparatide comparison did not differ significantly across the specified subgroups.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTreatment-subgroup interaction
    Study

    n = 43,352

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Source sentences

    Summary
    There were no significant treatment-subgroup interactions (P ≥ .2).
    3 context sentences
    Summary · context
    Times to first hip fracture, nonvertebral fracture, and serious cardiovascular event were compared between logistic regression-based propensity score-matched cohorts and in predefined subgroups by age, prior antiresorptive use, and prior fracture using Cox proportional hazards models.
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  6. 06HumanObservational studyEfficacy outcome

    In matched women, the teriparatide versus abaloparatide comparison showed no significant treatment-subgroup interactions.

    In plain wordsThe teriparatide versus abaloparatide comparison did not differ significantly across the specified subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTreatment-subgroup interaction
    Study

    n = 43,352

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Source sentences

    Summary
    There were no significant treatment-subgroup interactions (P ≥ .2).
    3 context sentences
    Summary · context
    Times to first hip fracture, nonvertebral fracture, and serious cardiovascular event were compared between logistic regression-based propensity score-matched cohorts and in predefined subgroups by age, prior antiresorptive use, and prior fracture using Cox proportional hazards models.
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  7. 07HumanObservational studySafety outcome

    In matched women, serious cardiovascular events were similar with abaloparatide and teriparatide.

    In plain wordsSerious cardiovascular events were similar with abaloparatide and teriparatide in matched women.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSerious cardiovascular events
    Study

    n = 43,352

    Comparator
    Teriparatide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Source sentences

    Summary
    Cardiovascular events were similar between groups.
    2 context sentences
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  8. 08HumanObservational studySafety outcome

    In matched women, serious cardiovascular events were similar with abaloparatide and teriparatide.

    In plain wordsSerious cardiovascular events were similar with abaloparatide and teriparatide in matched women.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSerious cardiovascular events
    Study

    n = 43,352

    Comparator
    Abaloparatide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 18 months (+ 30 days follow-up)As given in this study (human).

    Source sentences

    Summary
    Cardiovascular events were similar between groups.
    2 context sentences
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  9. 09HumanObservational studyOther

    Forty-five percent of women initiating abaloparatide had treatment exposure longer than 12 months in the matched cohort.

    In plain wordsForty-five percent of women who started abaloparatide received treatment for longer than 12 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableTreatment exposure longer than 12 months
    Study

    n = 21,676

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Treatment exposure longer than 12 months
    45%
    abaloparatide

    Source sentences

    Summary
    Forty-five percent of patients in the abaloparatide arm and 47% in the teriparatide arm were exposed to treatment for longer than 12 months.
    2 context sentences
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.
  10. 10HumanObservational studyOther

    In the matched cohort, 47% of women initiating teriparatide had treatment exposure longer than 12 months.

    In plain wordsAmong women who started teriparatide, 47% received treatment for longer than 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableTreatment exposure longer than 12 months
    Study

    n = 21,676

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Treatment exposure longer than 12 months
    47%
    teriparatide

    Source sentences

    Summary
    Forty-five percent of patients in the abaloparatide arm and 47% in the teriparatide arm were exposed to treatment for longer than 12 months.
    2 context sentences
    Summary · context
    This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.
    Summary · context
    Patients (21 676 per cohort) were well matched on 73 baseline parameters.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.